journal article·2025-04-01Open access

Treatment of Acute Liver Injury through Selective Tropism of High Mobility Group Box 1 Gene-Silenced Large Peritoneal Macrophages

Dhaval Oza, Fernando Ivich, Kirsten Deprey, Kelsey Bittner, Keith Bailey, Sarah Goldman, Mikyung Yu, Mark Niedre, Ho-Chou Tu, Mansoor M. Amiji

ACS Nano· Volume 19· Issue 12

Abstract

High Resolution Image Download MS PowerPoint Slide Tissue-resident macrophages (TRMs) are attractive cells to therapeutically deliver oligonucleotide and other gene-expression modifying modalities to treat a wide array of diseases ranging from inflammatory to autoimmune, and even cancer. Here, we focus on TRMs located inside the peritoneal cavity lining the abdomen that selectively express a transcription factor GATA6 called large peritoneal macrophages (GLPMs) and successfully demonstrate functional GLPM-selective delivery of a Cy5-fluorophore-labeled siRNA encapsulated in C12–200 cationic-lipidoid-based nanoparticles (siRNA-Cy5 (C12–200)). Despite being TRMs, GLPMs possess a specific migratory ability to peritoneally located liver tissue upon injury incited by acetaminophen (APAP) overdose in mice. A rapid, liver injury-driven tropism of GLPMs carrying siRNA-Cy5 (C12–200) was seen via systemic circulation, which was elegantly demonstrated by using a noninvasive live-cell tracking technique called diffuse in vivo flow cytometry (DiFC). Finally, RNAi-mediated silencing of a well-known pro-inflammatory damage-associated molecular pattern (DAMP) High Mobility Group Box-1 (HMGB1) gene in GLPMs led to the mitigation of liver injury and inflammation via prevention of GLPM modulation to a pro-inflammatory state, which further translated into significant protection from APAP-driven liver injury and a reduction in liver circulating pro-inflammatory cytokines owing to a muted inflammatory response to acute liver injury. Moreover, silencing HMGB1 by a GalNAc-conjugated hepatocyte-targeting siRNA did not reciprocate the findings, further solidifying our results. Together, our data suggested that GLPMs act as delivery carriers by rapidly bringing lipid nanoparticle-encapsulated RNAi modalities to the injured liver and have emerged as a therapeutically viable strategy to address inflammatory diseases, especially those that are more acute in nature.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Glycation End Products research · Endoplasmic Reticulum Stress and Disease · Aldose Reductase and Taurine

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States

Alnylam Pharmaceuticals, 675 West Kendall Street, Cambridge, Massachusetts 02142, United States

Department of Bioengineering, College of Engineering, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States

Department of Chemical Engineering, College of Engineering, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States

Funding

Northeastern University

References (40)

Show source-provided references
1. Oza, D.; Amiji, M. M. In Macrophage Targeted Delivery Systems: Basic Concepts and Therapeutic Applications; Gupta, S., Pathak, Y. V., Eds. Springer International Publishing, 2022; pp 357–378.10.1007/978-3-030-84164-5_16 ↗
2. 10.1126/sciimmunol.add196710.1126/sciimmunol.add1967 ↗
3. 10.1021/acs.nanolett.8b0068910.1021/acs.nanolett.8b00689 ↗
4. 10.1016/j.cell.2016.03.00910.1016/j.cell.2016.03.009 ↗
5. 10.1016/j.it.2022.12.00210.1016/j.it.2022.12.002 ↗
6. 10.1016/j.cell.2014.04.01610.1016/j.cell.2014.04.016 ↗
7. 10.1371/journal.pone.006141910.1371/journal.pone.0061419 ↗
8. 10.1038/s41467-021-27614-910.1038/s41467-021-27614-9 ↗
9. 10.1126/science.abe059510.1126/science.abe0595 ↗
10. 10.7150/thno.9106210.7150/thno.91062 ↗
11. 10.1038/s41586-023-06002-x10.1038/s41586-023-06002-x ↗
12. 10.3389/fphar.2019.0125510.3389/fphar.2019.01255 ↗
13. 10.1146/annurev-physiol-022516-03433910.1146/annurev-physiol-022516-034339 ↗
14. 10.1016/j.jhep.2016.11.01710.1016/j.jhep.2016.11.017 ↗
15. 10.1364/BOE.49926310.1364/BOE.499263 ↗
16. 10.1117/1.jbo.27.6.06700110.1117/1.jbo.27.6.067001 ↗
17. 10.1038/s41598-019-40143-210.1038/s41598-019-40143-2 ↗
18. 10.1117/1.jbo.27.9.09700210.1117/1.jbo.27.9.097002 ↗
19. 10.1016/j.jconrel.2024.08.03010.1016/j.jconrel.2024.08.030 ↗
20. 10.1073/pnas.091060310610.1073/pnas.0910603106 ↗
21. 10.1038/mtna.2011.310.1038/mtna.2011.3 ↗
22. 10.1038/s12276-022-00736-w10.1038/s12276-022-00736-w ↗
23. 10.1196/annals.1398.00810.1196/annals.1398.008 ↗
24. 10.1007/s10565-024-09893-210.1007/s10565-024-09893-2 ↗
25. 10.1186/s12860-023-00464-710.1186/s12860-023-00464-7 ↗
26. 10.1007/s12072-018-9911-910.1007/s12072-018-9911-9 ↗
27. 10.1080/17474124.2017.134562510.1080/17474124.2017.1345625 ↗
28. 10.1111/j.1572-0241.2007.01388.x10.1111/j.1572-0241.2007.01388.x ↗
29. 10.1056/NEJMra120893710.1056/NEJMra1208937 ↗
30. 10.1038/nri159410.1038/nri1594 ↗
31. 10.1039/C4TX00193A10.1039/C4TX00193A ↗
32. 10.1021/acsami.9b2300410.1021/acsami.9b23004 ↗
33. 10.1093/nar/gkaa67010.1093/nar/gkaa670 ↗
34. 10.1096/fasebj.8.2.811949210.1096/fasebj.8.2.8119492 ↗
35. 10.1093/toxsci/kfg18110.1093/toxsci/kfg181 ↗
36. 10.1002/cbic.20150002310.1002/cbic.201500023 ↗
37. 10.1111/febs.1604610.1111/febs.16046 ↗
38. 10.4161/cc.5.8.264610.4161/cc.5.8.2646 ↗
39. 10.1152/ajpcell.00238.201510.1152/ajpcell.00238.2015 ↗
40. 10.1038/s41565-023-01444-w10.1038/s41565-023-01444-w ↗